These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32710148)

  • 21. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
    Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
    Tezuka T; Hamada C; Ishida H; Ooshiro M; Matsuoka H; Kawasaki S; Mishima H; Maeda K; Sakamoto J; Koda K
    Invest New Drugs; 2013 Oct; 31(5):1321-9. PubMed ID: 23817973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
    Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
    Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
    Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
    Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
    BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFOXIRI Plus Panitumumab As First-Line Treatment of
    Modest DP; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Ricke J; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Geissler M
    J Clin Oncol; 2019 Dec; 37(35):3401-3411. PubMed ID: 31609637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
    Chen EX; Kavan P; Tehfe M; Kortmansky JS; Sawyer MB; Chiorean EG; Lieu CH; Polite B; Wong L; Fakih M; Spencer K; Chaves J; Li C; Leconte P; Adelberg D; Kim R
    Clin Colorectal Cancer; 2024 Jun; 23(2):183-193. PubMed ID: 38653648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D.
    Kim R; Tehfe M; Kavan P; Chaves J; Kortmansky JS; Chen EX; Lieu CH; Wong L; Fakih M; Spencer K; Zhao Q; Predoiu R; Li C; Leconte P; Adelberg D; Chiorean EG
    Clin Colorectal Cancer; 2024 Jun; 23(2):118-127.e6. PubMed ID: 38762348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
    Morelli MF; Santomaggio A; Ricevuto E; Cannita K; De Galitiis F; Tudini M; Bruera G; Mancini M; Pelliccione M; Calista F; Guglielmi F; Martella F; Lanfiuti Baldi P; Porzio G; Russo A; Gebbia N; Iacobelli S; Marchetti P; Ficorella C
    Oncol Rep; 2010 Jun; 23(6):1635-40. PubMed ID: 20428819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
    Pentheroudakis G; Kotoula V; Koliou GA; Karavasilis V; Samantas E; Aravantinos G; Kalogeropoulou L; Souglakos I; Kentepozidis N; Koumakis G; Sgouros J; Zarkavelis G; Efstratiou I; Laschos K; Petraki C; Tikas I; Poulios C; Voutsina A; Goudopoulou A; Bafaloukos D; Vrettou E; Kalogera-Fountzila A; Pectasides D; Fountzilas G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e631-e637. PubMed ID: 29980490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C
    J Clin Oncol; 2024 Aug; 42(22):2637-2644. PubMed ID: 38865678
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.